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Two molecules of an antitumor agent, 5-fluorodeoxyuridine (5-FdUrd), were connected 
by a 2-oxoalkyl linker (Oxo-linker) at the N(3) position to obtain radiation-activated 
prodrugs, FdUrd2 A and FdUrd2 B. The prodrugs in this study released 5-FdUrd via 
one-electron reduction initiated by hypoxic X-irradiation. The release of 5-FdUrd from 
FdUrd2 A and FdUrd2 B proceeded more efficiently than that of previous prodrug, 
Oxo-FdUrd, which possessed one molecule of 5-FdUrd. FdUrd2 A exhibited increased 
cytotoxicity against A549 cells when the FdUrd2 A solution had been irradiated with a 
large dose of X-rays before administration to the cells. However, we observed no effect 
on cytotoxicity when the cells were X-irradiated under hypoxic conditions in the 
presence of FdUrd2 A because the amount of 5-FdUrd released in the cells seemed to be 




A number of stimuli-responsive prodrugs have been developed and investigated 
extensively with the aim of maximizing their potential and minimizing side effects. 







been used to activate prodrugs to express their original activities. The use of 
stimuli-responsive prodrugs offers an interesting opportunity for the efficient and 
precise onset of drug potency.
10,11
 
One new strategy is the use of X-irradiation as an external trigger to activate a 
prodrug.
12-17
 Since the chemical reactions triggered by this stimulation can be controlled 
spatially and temporally, the prodrug can be converted to its active form with exact 
control over the area, time, and dosage. The prodrug does not exhibit cytotoxicity 
without irradiation, but a prodrug can be activated irreversibly by X-irradiation to 
produce the original cytotoxicity by removing labile substituents to form parent drug. 
We have identified a series of 2-oxoalkyl groups as reactive substituents that are 
removable by hypoxic X-irradiation in aqueous solution.
18-21
 An activation mechanism 




) generated via radiolysis of water to form the corresponding * 
anion radical, followed by thermal activation into the * anion radical, which is readily 
hydrolyzed to release the 2-oxoalkyl group. We have applied these characteristics of the 
2-oxoalkyl group to develop the following prodrugs: 1-(2’-oxopropyl)-5-fluorouracil,18 
2’-deoxy-5-fluoro-3-(2’-oxoalkyl)uridine20 and 
4-(2-oxopropylamino)-1-(-arabinofuranosyl)pyrimidine-2-one.,21 These were activated 
to release 5-fluorouracil (5FU), 5-fluoro-2’-deoxyuridine (5-FdUrd) and cytarabine 
upon hypoxic X-irradiation. Because of the highly cytotoxic effect, these drugs have 
been widely used as an antineoplastic and antiviral agent. However, high dose of drug 
causes serious side effects, and thereby there has been a demand for giving a target 
specific feature to drugs that could discriminate between tumor and normal cells for 
cytotoxicity. 
Herein, we describe our design of the radiation-activated prodrug of 5-FdUrd, FdUrd2 A 
and FdUrd2 B (Figure 1), to establish guides for the molecular design of 5-FdUrd 
prodrugs. For an emergence of highly potent cytotoxicity, two 5-FdUrd units were 
connected with a 2-oxoalkyl linker (Oxo-linker) to produce the prodrugs, which 
 6 
undergo one-electron reduction by X-irradiation to liberate the two parent drugs of 
5-FdUrd. The release of 5-FdUrd upon X-irradiation proceeded predominantly under 
hypoxic conditions, which has been identified as one of the most important features of 
solid tumors.
22
 We report on the synthesis of the prodrugs and characterization of their 




Results and Discussion 
The syntheses of the 5-FdUrd derivatives, FdUrd2 A and FdUrd2 B, are outlined in 
Scheme 1. Two molecules of acetylated 5-FdUrd 1
23
 were coupled with 
1,3-dibromo-2-propanone, and the acetyl groups were then removed under basic 
conditions to give FdUrd2 A.
24
 FdUrd2 B and the control compound FdUrd2 C were 








We performed the one-electron reduction of FdUrd2 A using X-radiolysis in 
argon-purged aqueous solution containing an excess amount of 2-methyl-2-propanol, 
which scavenges hydroxyl radicals to suppress any possible side reactions.
25
 Under 
these conditions, hydrated electrons (eaq
–
) are generated as one of the active species by 
the radiolytic degradation of water molecules. The representative reaction profile of 
FdUrd2 A is shown in Figure 2. Hypoxic X-irradiation of FdUrd2 A induced the 
formation of a single new product, which was assigned as 5-FdUrd according to the 
overlapped injection of authentic sample. As shown in Table 1, the G values
26
 for the 
decomposition of FdUrd2 A and the formation of 5-FdUrd were estimated to be 319.1 
and 125.9 nmol/J, respectively. In contrast to the efficient reaction upon hypoxic 
X-irradiation, the release of 5-FdUrd from FdUrd2 A was less efficient upon 
X-radiolysis under aerobic conditions, under which a significant amount of the starting 
material, FdUrd2 A, was recovered. In view of the well-documented evidence that 
molecular oxygen captures reducing species eaq
-
 to inhibit the reduction, the hypoxic 
 8 
radiolysis of FdUrd2 A is most likely to occur via one-electron reduction by eaq
-
 in a 
hypoxia selective manner. We also confirmed that a similar reaction for FdUrd2 B 
proceeded to release 5-FdUrd upon hypoxic X-irradiation; however, the formation 
efficiency of 5-FdUrd from FdUrd2 B was slightly lower than that from FdUrd2 A. In a 
separate experiment, radiolysis of the control compound FdUrd2 C failed to release 
5-FdUrd, indicating that a carbonyl group in the Oxo-linker is indispensable for the 
radiolytic release of 5-FdUrd. 
 
(Figure 2 and Table 1) 
 
We compared the radiolytic release of 5-FdUrd from FdUrd2 A with that from a 
previous prodrug, Oxo-FdUrd, which has one 5-FdUrd unit intramolecularly.
20
 As 
shown in Table 1, the two compounds showed similar G values for the decomposition, 
whereas the G value for the formation of 5-FdUrd derived from the radiolysis of FdUrd2 
A was larger than that of Oxo-FdUrd. These results strongly indicate that FdUrd2 A has 
greater ability to release 5-FdUrd than does Oxo-FdUrd because FdUrd2 A possesses 
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two units of 5-FdUrd. 
To understand the function of FdUrd2 A and FdUrd2 B in living cells, we next assessed 
their cytotoxic properties toward the human cell line of lung adenocarcinoma A549 
(Figure 3). The cells were cultured for 72 h in the presence of various concentrations of 
FdUrd2 A, FdUrd2 B, or 5-FdUrd, and were subsequently subjected to a cell viability 
assay. The IC50 values of each drug were estimated to be 4.66, 1.04, and 0.0124 M for 
FdUrd2 A, FdUrd2 B, and 5-FdUrd, respectively. These findings indicate that 
modification and dimerization of 5-FdUrd by the Oxo-linker can effectively reduce the 




The lowered cytotoxicity of 5-FdUrd derivatives possessing the Oxo-linker motivated 
us to investigate the effect of X-irradiation on drugs’ functions. Of the two compounds 
possessing the Oxo-linker, we chose FdUrd2 A to characterize the radiation-induced 
enhancement of cytotoxicity because it showed more favorable properties as a 
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radiation-activated prodrug than FdUrd2 B; e.g. the cytotoxicity of FdUrd2 A was lower 
than that of FdUrd2 B, and FdUrd2 A showed more sensitive reactivity toward radiolytic 
one-electron reduction. Although the effect of the substituent on the cytotoxicity and 
sensitivity was unclear, the changes in lipophilicity and electron affinity induced by 
introduction of methyl group into Oxo-linker may cause differences in these properties.    
An aqueous solution of FdUrd2 A was X-irradiated under hypoxic or aerobic conditions, 
and the resulting solution was then administered to A549 cells. As shown in Figure 4A, 
X-irradiated FdUrd2 A under aerobic conditions showed a slight cytotoxic effect, which 
is consistent with the evidence that the efficiency of 5-FdUrd release upon aerobic 
irradiation was lower than that upon hypoxic irradiation. By contrast, the cell viability 
was significantly reduced when the hypoxically irradiated FdUrd2 A was administered. 
These results indicate that the 5-FdUrd released from FdUrd2 A by radiolysis increased 
the cytotoxicity toward A549 cells. Given that the G values for the formation of 
5-FdUrd from FdUrd2 A was 125.9 nmol/J, the amount of 5-FdUrd released upon 120 
Gy irradiation is seemed to exceed IC50 values of 5-FdUrd against A549 cells.  
We next tried the radiolytic activation of FdUrd2 A in the cells. FdUrd2 A was 
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administered to the cells, and then incubated for 12 h. After the incubation, the cells 
were X-irradiated up to 6 Gy under hypoxic conditions. Although an increase in 
cytotoxicity by the release of 5-FdUrd was expected, we observed no effect on 
cytotoxicity or cell viability (Figure 4B). Given that > 10 Gy X-irradiation was required 
to increase the cytotoxicity of the prodrug in the experiments using preirradiated FdUrd2 
A (Figure 4A), the amount of 5-FdUrd released in the cells by 6 Gy irradiation seemed 
to be too low to express its original cytotoxicity. We could not increase the radiation 






We prepared 5-FdUrd derivatives, in which two units of 5-FdUrd were linked by a 
radiation-sensitive Oxo-linker, and characterized their radiolytic one-electron reduction. 
FdUrd2 A and FdUrd2 B were activated by X-irradiation to release 5-FdUrd under 
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hypoxic conditions. By contrast, the release of 5-FdUrd was suppressed significantly 
upon aerobic irradiation because eaq
-
, which are key reducing species for activation, 
were captured by molecular oxygen. A biological assay using A549 cells revealed that 
pretreatment of FdUrd2 A with X-irradiation caused enhanced cytotoxicity by releasing 
a sufficient amount of 5-FdUrd. However, increased cytotoxicity was not observed, 
when the cells were irradiated in the presence of FdUrd2 A under hypoxic conditions. 
We presumed that the amount of 5-FdUrd released from FdUrd2 A in the cells upon 
low-dose X-irradiation was inadequate for onset of cytotoxicity. Improvements to 
enhance the efficiency of the radiolytic release of 5-FdUrd are underway. 
 
Acknowledgement: This work is partly supported by the Strategic Promotion Program 
for Basic Nuclear Research from the Ministry of Education, Culture, Sports, Science 




General Procedures. All starting materials and reagents were purchased from Tokyo 
Kasei Kogyo (Tokyo, Japan), Wako (Tokyo, Japan) and Aldrich Chemical (Milwaukee, 
WI). All other solvents, purchased from Wako, were GR grade or dry grade and used 
without further purification. Oxo-FdUrd
20
 were synthesized as described previously. 
The 
1
H NMR spectra were recorded using a JOEL JNM-AL400 (400MHz) spectrometer 
in CDCl3. Coupling constants are given in hertz. 
13
C NMR spectra were measured with 
JOEL JMN-AL-400 (100 MHz) spectrophotometer in DMSO-d6 or CDCl3. The 
FAB-MS spectra were recorded on a JOEL JMS-SX102A spectrometer, using 
nitrobenzyl alcohol or glycerol as matrix. The organic reactions were carried out in 
oven-dried glassware under an argon atmosphere with magnetic stirring. 
High-Performance liquid chromatography (HPLC) was carried out with a Hitachi HPLC 
system (L-7455 Diode array detector, L-7300 column oven, L-7100 pump, D-7000 
interface). Sample solutions were injected onto a reversed-phase column (Inertsil 
ODS-3, GL Science Inc.). The solvent mixture of 0.1 M triethylamine acetate (TEAA) 
at pH 7.0 and 100% acetonitrile was delivered as mobile phase at a flow rate of 0.6 mL 
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or 3.0 mL / min at 40 ˚C. The column eluents were monitored by the UV absorbance at 
260 nm. Rigaku RADIOFLEX-350 was used for X-radiolysis. 
 
1,3-Bis[5-fluoro-1-(-2’-deoxy-3’,5’-di-O-acetylribofuranosyl)-2,4-dioxopyrimidiny
l]-propanone (2A).  General procedure for alkylation of 
2’-deoxy-3’,5’-di-O-acetyl-5-fluorouridine at N(3)-position. Sodium hydride (42 mg, 
1.12 mmol) was added to a solution of 2’-deoxy-3,5’-di-O-acetyl-5-fluorouridine (300 
mg, 0.91 mmol) in anhydrous DMF (5 mL) at 0 ˚C and the mixture was stirred at 0 ˚C 
for 15 min. To the resulting mixture was added a solution of 1,3-dibromopropanone 
(98.1 mg, 0.45 mmol) in anhydrous DMF (761 L) and the mixture was stirred at 
ambient temperature for 24 h. The reaction mixture was diluted with saturated 
ammonium chloride and then extracted with ethyl acetate. The extract was washed with 
brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude product was 
purified by column chromatography (SiO2, 2.5% MeOH/CHCl3) to give 2A (231 mg, 
71%) as a white solid: Mp 140–141 ˚C; 1H NMR (CDCl3, 400 MHz)  2.09 (s, 6H), 
2.12 (s, 6H), 2.14–2.19 (m, 2H), 2.55 (ddd, 2H, J = 16.0, 8.0, 2.0 Hz) 4.25–4.27 (m, 2H) 
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4.30 (dd, 2H, J = 12.2, 3.4 Hz), 4.38 (dd, 2H, J = 12.2, 3.4 Hz), 4.78 (d, 2H, J = 17.1 
Hz), 4.93 (d, 2H, J = 16.6 Hz), 5.18 (ddd, 2H, J = 5.9, 2.9, 2.9 Hz), 6.27 (dd, 2H, J = 
6.5, 6.5 Hz), 7.67 (d, 2H, J = 5.8 Hz); 
13
C NMR (CDCl3, 100 MHz)  20.7, 20.8, 38.0, 
47.8, 63.7, 73.9, 82.6, 86.2, 121.9 (d, J = 34.7 Hz), 140.1 (d, J = 241.7 Hz), 148.6, 156.0 
(d, J = 26.4 Hz), 170.0, 170.3, 194.8; FABMS (NBA) m/z 715 [(M+H)
+
]; HRMS calcd 
for C29H32F2N4O15 [(M+H)
+
] 715.1905, found 715.1940. 
 
1,5-Bis[5-fluoro-1-(-2’-deoxy-3’,5’-di--acetylribofuranosyl)-2,4-dioxopyrimidiny
l]-2,4-dimethylpropanone (2B). According to the method detailed for 2A, the reaction 
of 2,4-dibromo-3-pentanone (69.4 L, 0.45 mmol) gave 2B (65.9 mg, 20%) as a white 
solid: Mp 85–86 ˚C; 1H NMR (DMSO-d6, 400 MHz)  1.36 (d, 6H, 6.8 Hz), 2.05 (s, 
12H), 2.34–2.39 (m, 4H), 4.16–4.19 (m, 2H), 4.24–4.27 (m, 4H), 5.16–5.20 (m, 2H), 
5.36 (q, 2H, J = 4.4 Hz), 6.16 (t, 2H, J = 7.3 Hz), 8.13 (d, 2H, J = 6.3 Hz); 
13
C NMR 
(CDCl3, 100 MHz)  13.5 (d, J = 100 MHz), 20.7, 20.8, 38.0, 54.6 (d, J = 95.4), 63.7, 
73.7, 82.7, 86.2, 122.0 (d, J= 36.4 Hz), 140.0 (d, J = 235.6 Hz), 148.6, 156.2 (d, J = 
23.1 Hz), 170.1, 170.3, 197.7; FABMS (NBA) m/z 743 [(M+H)
+




] 743.2218, found 743.2203. 
 
1,3-Bis[5-fluoro-1-(-2’-deoxy-3’,5’-di--acetylribofuranosyl)-2,4-dioxopyrimidiny
l]-propane (2C). According to the method detailed for 2A, the reaction of 
1,3-dibromopropane (45.3 L, 0.44 mmol) gave 2C (191.3 mg, 63%) as a white solid: 
Mp 125–127 ˚C; 1H NMR (DMSO-d6, 400 MHz) 1.80–1.85 (m, 2H), 2.04 (s, 6H), 
2.05 (s, 6H), 2.30–2.36 (m, 2H), 2.42–2.46 (m, 2H), 3.81 (t, 4H, J = 6.8), 4.16–4.19 (m, 
2H), 4.24–4.27 (m, 4H), 5.16–5.20 (m, 2H), 6.17 (t, 2H, J = 5.8 Hz), 8.03 (d, 2H, J = 
6.4 Hz); 
13
C NMR (CDCl3, 100 MHz)  20.7, 20.8, 25.9, 38.0, 39.4, 63.7, 73.8, 82.5, 
86.0, 121.2 (d, J = 34.7 Hz), 140.2 (d, J = 234.7 Hz), 149.1, 156.5 (d, J = 25.6 Hz), 
170.1, 170.3; FABMS (NBA) m/z 701 [(M+H)
+
]; HRMS calcd for C29H34F2N4O14 
[(M+H)
+
] 701.2112, found 701.2122. 
 
1,3-Bis[5-fluoro-1-(-2’-deoxyribofuranosyl)-2,4-dioxopyrimidinyl]propanone 
(FdUrd2 A). General procedure for hydrolysis. To a solution of 2A (48 mg, 0.068 
mmol) in THF (2 mL) and methanol (2 mL) was added aqueous sodium hydroxide (0.1 
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M, 170 L, 0.017 mmol) and the mixture was stirred at 0 ˚C for 5 h. The reaction 
mixture was concentrated in vacuo and the crude product was purified by column 
chromatography (SiO2, 20% MeOH/CHCl3) to give FdUrd2 A (37 mg, quant.) as a 
white solid: Mp 129–131 ˚C; 1H NMR (DMSO-d6, 400 MHz)  2.12–2.14 (m, 4H), 
3.55–3.66 (m, 4H), 3.79–3.82 (m, 2H), 4.23–4.27 (m, 2H), 4.88 (s, 4H), 5.19 (t, 2H, J = 
5.4 Hz), 5.27 (d, 2H, J = 4.4 Hz), 6.14 (t, 2H, J = 6.4 Hz), 8.38 (d, 2H, J = 6.8 Hz); 
13
C 
NMR (DMSO-d6, 100 MHz)  39.9, 47.9, 60.8, 69.9, 85.6, 87.7, 124.1 (d, J = 34.2 Hz), 
139.2 (d, J = 229.4 Hz), 148.5, 155.9 (d, J = 25.8 Hz), 196.9; FABMS (glycerol) m/z 
547 [(M+H)
+
]; HRMS calcd for C21H24F2N4O11 [(M+H)
+
] 547.1482, found 547.1501. 
 
1,5-Bis[5-fluoro-1-(-2’-deoxyribofuranosyl)-2,4-dioxopyrimidinyl]-2,4-dimethylpr
opanone (FdUrd2 B). According to the method detailed for FdUrd2 A, the reaction of 
2B (20 mg, 0.027 mmol) gave FdUrd2 B (13.3 mg, 87%) as a white solid: Mp 136–140 
˚C; 1H NMR (DMSO-d6, 400 MHz)  1.35 (d, 6H, J = 6.8 Hz), 2.17 (dd, 4H, J = 11.9, 
6.3 Hz), 3.56–3.67 (m, 4H), 3.81 (t, 4H, J = 2.7 Hz), 4.22–4.27 (m, 2H), 5.20 (t, 2H, J = 
4.9 Hz), 5.27 (dd, 2H, J = 4.8, 1.6 Hz), 5.35 (q, 2H, J = 6.8 Hz), 6.11 (dd, 2H, J = 10.9, 
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5.6 Hz), 8.38–8.40 (m, 1H); 13C NMR (DMSO-d6, 100 MHz)  13.1 (d, J = 108.6), 40.0, 
60.7, 69.7, 85.8, 87.7, 124.3 (d, J = 35.0 Hz), 139.3 (d, J = 228.6), 148.3, 156.0 (d, J = 
25.8 Hz), 198.6; FABMS (glycerol) m/z 575 [(M+H)
+
]; HRMS calcd for C23H28F2N4O11 
[(M+H)
+
] 575.1795, found 575.1814. 
 
1,3-Bis[5-fluoro-1-(-2’-deoxyribofuranosyl)-2,4-dioxopyrimidinyl]propane 
(FdUrd2 C). According to the method detailed for FdUrd2 A, the reaction of 2C (26 mg, 
0.037 mmol) gave FdUrd2 C (20 mg, quant.) as a yellow solid: Mp 105–107 ˚C; 
1
H 
NMR (DMSO-d6, 400 MHz)  1.82 (quint, 2H, J = 7.1 Hz), 2.10–2.16 (m, 4H), 
3.54–3.66 (m, 4H), 3.78–3.82 (m, 6H), 4.23 (q, 2H, J = 4.0 Hz), 5.18 (t, 2H, J = 4.0 Hz), 
5.25 (d, 2H, J = 4.4 Hz), 6.15 (t, 2H, J = 6.4 Hz), 8.30 (d, 2H, J = 6.8 Hz); 
13
C NMR 
(DMSO-d6, 100 MHz)  25.2, 40.0, 48.6, 60.8, 69.8, 85.5, 87.6, 123,5 (d, J = 36.9 Hz), 
139.4 (d, J = 227.3 Hz), 148.8, 156.4 (d, J = 25.6 Hz); FABMS (glycerol) m/z 533 
[(M+H)
+
]; HRMS calcd for C21H26F2N4O10 [(M+H)
+
] 533.1690, found 533.1683. 
 
Radiolytic reduction. Aqueous solutions of FdUrd2 A, FdUrd2 B, and FdUrd2 C (100 
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M), containing 2-methyl-2-propanol (5 mM), were purged with argon for 10 min and 
then irradiated in a sealed glass ampoule at ambient temperature with an X-ray source 
(6.0 Gy min
-1
). After the X-irradiation, the solution was subjected to HPLC analysis. 
Since the lower detection limit of the prodrugs and 5-FdUrd by HPLC was micromolar 
level, we needed large dose of X-irradiation for activation of prodrugs at submilimolar 
level.  
 
Assessment of cytotoxicity toward A549 cells. A549 cells were cultured in Dulbecco’s 
modified Eagle’s minimum essential medium (DMEM) containing 10% fetal bovine 
serum (FBS) and 1% antibiotics (mixture of streptomycin, penicillin). The cells were 
seeded into 96-well plates (1500 cells/well) and cultured at 37 ˚C in a well-humidified 
incubator with 5% CO2 and 95% air (aerobic condition) for 24 h. The cells were then 
incubated with the various concentrations of FdUrd2 A, FdUrd2 B, or 5-FdUrd under 
aerobic conditions for 72 h, and added with 10 L of Cell Counting Kit-8 (Dojindo). 
The plates were further incubated at 37 ˚C for 30 min and the cell viability assay was 
performed using Microplate Reader (BIO-RAD). 
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Radiation-induced cytotoxicity of pre-irradiated FdUrd2 A. DMEM solutions of 
FdUrd2 A under hypoxic or aerobic conditions were prepared and then irradiated in a 
sealed glass ampoule at ambient temperature with an X-ray source (6.0 Gy min
-1
). A549 
cells were seeded into 96-well plaets (1500 cells/well) and cultured at 37 ˚C under 
aerobic condition for 24 h. The cells were then incubated with irradiated FdUrd2 A 
under aerobic conditions for 72 h. After adding 10 L of Cell Counting Kit-8 to each 
well, and the cell viability assay was performed as described above. 
 
Radiation-induced cytotoxicity of FdUrd2 A (X-irradiation to cells in the presence 
of FdUrd2 A). A549 cells were seeded into 96-well plates (1500 cells/well) and 
incubated at 37 ˚C for 6 h under hypoxic conditions. The cells were then incubated with 
FdUrd2 A at 37 ˚C under hypoxic condition for 12 h. For the hypoxic treatment (< 0.3% 
of oxygen), the cells were treated in a hypoxic chamber, INVIVO2 400 (Ruskinn 
Technology Ltd.). The plates kept under hypoxic conditions using Anaero Pack System 
(Mitsubishi Gas Chemical Company Inc., Japan) were treated with X-rays at a dose of 6 
 21 
Gy and incubated for 72 h under aerobic conditions. After adding 10 L of Cell 
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Table 1. G-Values for X-radiolysis of FdUrd2 A-C (100 M) and Oxo-FdUrd (100 M) 
in aqueous solution containing 2-methyl-2-propanol (5 mM) under hypoxic or aerobic 
conditions 
 Hypoxic conditions  Aerobic conditions 
















FdUrd2 A 319.1 125.9  173.6 14.5 
FdUrd2 B 291.0 115.3  177.2 26.2 
FdUrd2 C 148.8 <1.0  140.3 1.4 










Scheme 1. Reagents and conditions: (a) 1,3-dibromo-2-propanone (for 2A), 
2,4-dibromo-3-pentanone (for 2B), 1,3-dibromopropane (for 2C), NaH, DMF, 71% (for 
2A), 20% (for 2B), 63% (for 2C); (b) NaOH, THF, MeOH,  quant. (for FdUrd2 A), 




Figure 1. Chemical structure of prodrugs and drug (FdUrd2 A, FdUrd2 B, FdUrd2 C and 
















Figure 2. HPLC profiles for the one-electron reduction of FdUrd2 A (100 M) in the 
X-radiolyses (0 and 360 Gy) of aqueous solution containing 2-methyl-2-propanol (5 
















Figure 3. Cytotoxicity of FdUrd2 A (circle), FdUrd2 B (square) and 5-FdUrd (triangle) 
against A549 tumor cells. A549 cells were incubated with indicated concentration of 
FdUrd2 A, FdUrd2 B and 5-FdUrd under aerobic conditions. The cell viability was 
calculated by means of cell counting kit-8 (WST-8). Results are shown with the mean ± 




Figure 4. Radiation-induced cytotoxicity of FdUrd2 A against A549 cells. (A) Aqueous 
solutions of FdUrd2 A (1 M) was X-irradiated (0, 30, 60 or 120 Gy) under aerobic or 
hypoxic conditions, and then administered to cells. (B) A549 cells were cultured in the 
presence (+) or absence (-) of 125 nM FdUrd2 A, and treated with X-ray (0 or 6 Gy) 
under hypoxic conditions. Results are shown with the mean ± S.D (n = 6 for (A), n= 9 
for (B)). 
 
 
 
 
